![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: APLP1 |
Gene summary for APLP1 |
![]() |
Gene information | Species | Human | Gene symbol | APLP1 | Gene ID | 333 |
Gene name | amyloid beta precursor like protein 1 | |
Gene Alias | APLP | |
Cytomap | 19q13.12 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | P51693 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
333 | APLP1 | ATC09 | Human | Thyroid | ATC | 2.26e-06 | 4.26e-01 | 0.2871 |
333 | APLP1 | ATC12 | Human | Thyroid | ATC | 4.82e-02 | 9.53e-02 | 0.34 |
333 | APLP1 | ATC13 | Human | Thyroid | ATC | 3.33e-45 | 7.61e-01 | 0.34 |
333 | APLP1 | ATC1 | Human | Thyroid | ATC | 1.52e-06 | 4.77e-01 | 0.2878 |
333 | APLP1 | ATC2 | Human | Thyroid | ATC | 2.49e-06 | 7.18e-01 | 0.34 |
333 | APLP1 | ATC4 | Human | Thyroid | ATC | 1.21e-03 | 1.34e-01 | 0.34 |
333 | APLP1 | ATC5 | Human | Thyroid | ATC | 1.51e-42 | 8.35e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | ![]() |
Oral cavity | LP | ![]() |
Oral cavity | EOLP | ![]() |
Oral cavity | NEOLP | ![]() |
Esophagus | HGIN | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003019812 | Thyroid | ATC | extracellular matrix organization | 152/6293 | 301/18723 | 8.63e-10 | 2.24e-08 | 152 |
GO:004306212 | Thyroid | ATC | extracellular structure organization | 152/6293 | 302/18723 | 1.17e-09 | 2.94e-08 | 152 |
GO:004522912 | Thyroid | ATC | external encapsulating structure organization | 152/6293 | 304/18723 | 2.11e-09 | 5.08e-08 | 152 |
GO:003090015 | Thyroid | ATC | forebrain development | 164/6293 | 379/18723 | 4.85e-05 | 3.87e-04 | 164 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
APLP1 | SNV | Missense_Mutation | c.733N>A | p.Glu245Lys | p.E245K | P51693 | protein_coding | tolerated(0.36) | benign(0.157) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
APLP1 | SNV | Missense_Mutation | c.483N>C | p.Gln161His | p.Q161H | P51693 | protein_coding | deleterious(0.01) | probably_damaging(0.917) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
APLP1 | SNV | Missense_Mutation | novel | c.1540N>T | p.Asp514Tyr | p.D514Y | P51693 | protein_coding | tolerated(0.14) | benign(0.243) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
APLP1 | SNV | Missense_Mutation | novel | c.1714N>T | p.Ala572Ser | p.A572S | P51693 | protein_coding | tolerated(0.57) | benign(0.116) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
APLP1 | SNV | Missense_Mutation | c.1942N>C | p.Glu648Gln | p.E648Q | P51693 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A18V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
APLP1 | SNV | Missense_Mutation | novel | c.268C>A | p.Arg90Ser | p.R90S | P51693 | protein_coding | tolerated(0.09) | benign(0.365) | TCGA-E2-A1AZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
APLP1 | SNV | Missense_Mutation | novel | c.488N>A | p.Arg163His | p.R163H | P51693 | protein_coding | deleterious(0.01) | probably_damaging(0.922) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
APLP1 | SNV | Missense_Mutation | c.1658N>T | p.Ala553Val | p.A553V | P51693 | protein_coding | tolerated(0.66) | benign(0) | TCGA-EA-A3HQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
APLP1 | SNV | Missense_Mutation | rs763547342 | c.1223N>A | p.Arg408His | p.R408H | P51693 | protein_coding | tolerated(0.32) | benign(0.154) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
APLP1 | SNV | Missense_Mutation | c.1081N>G | p.Leu361Val | p.L361V | P51693 | protein_coding | deleterious(0) | possibly_damaging(0.756) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |